EditorPhoto(chemo)therapy is a well established psoriasis therapy. As demonstrated by Parrish and Jaenicke, the action spectrum for psoriasis clearing is 300-313 nm. 1 In recent years, targeted UVB phototherapy with 308 nm-excimer laser and excimer light has been developed. It avoids unnecessary UV-exposure of non-lesional skin and allows higher dosages for lesional skin what results in a more rapid clearing. Both seem to achieve comparable efficacy with lower investment costs for excimer light. [2][3][4][5] We report a pilot trial in moderate plaque-type adult psoriasis patients using a newly developed 307 nm-excimer lamp compared to topical dithranol.This is an open clinical pilot trial with permission from the local ethical committee. Every patient served as his ⁄ her own control. Systemic therapy was not allowed. Two target lesions of comparable size and plaque-modified Psoriasis Activity and Severity Index (PSI) scores 6 were selected for monitoring. Lesion A was treated with 307 nm-excimer light only. Lesion B was treated with dithranol.Targeted UVB treatment was performed with a new device three times starting with the minimal erythema dose (MED). The mean 307 nm-excimer light exposure per session was 20 s resulting in a mean total irradiation time of 37 s. With the support of a quartz bar targeted treatment with a focus area of 3 cm 2 is realized. The average UVB med irradiance was 18 mW ⁄ cm 2 , maximum 20 mW ⁄ cm 2 . The average total energy applied was 2.05 J, with 1.13 J in the UVB med range. We used the fluorescence-remission imaging (FRIS) as described before 7 for non-invasive objective measurements.A total of 21 patients were recruited with 19 patients completing the investigation [15 men, six women]. The mean age was 51 years (range 26-84 years). All patients had a Fitzpatrick skin phototype II or III. The mean improvement of the PSI score was 3.0 for lesion A (three times excimer light) and for lesion B (twice daily dithranol) (P = 0.965; Mann-Whitney U-test). The results clearly demonstrate an equipotency of the targeted phototherapy to topical dithranol (Table 1).Tolerance was superior with targeted phototherapy. The most common adverse effect in excimer light-treated lesions was a mild to moderate erythema (n = 11), temporary blistering (n = 3), but there was no scarring or oozing. The NADH-fluorescence is reduced in psoriatic lesions. Excimer light treatment results in a normalization of NADH-fluorescence in contrast to dithranol.The UVB-excimer lamps are an alternative for targeted UVBtherapy in psoriasis. They seem to be as effective as non-targeted narrow-band UVB and 308 nm-excimer laser therapy. 4,5 There has been no study comparing targeted UVB phototherapy with topical treatments. In this study for the first time 307 nm-excimer light therapy was compared to topical dithranol therapy. Dithranol is one of the most potent topical antipsoriatic drugs. 8 We used a newly developed 307 nm-excimer light for targeted UVB-therapy and compared its efficacy and safety to topical dithranol twice d...
The 307 nm excimer light therapy for plaque type psoriasis was equipotent to twice daily topical dithranol. Efficacy, safety, and convenience suggest that targeted UVB therapy with quasi monochromatic light is a new useful treatment option for patients with limited psoriatic plaques.
Phototherapy involves exposure of the skin to light in order to treat various skin diseases such as psoriasis. In the 20th century, great advancements have been made in developing safe and effective narrowband ultraviolet B (NB‐UVB) phototherapy modalities. Targeted phototherapy delivers light exclusively to the affected skin and thereby avoids side effects on unaffected healthy areas. Recently, solid‐state UV light emitting diodes (UV LEDs) have the potential to become the light source of the future for targeted NB‐UVB phototherapy treatments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.